Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Recurrent Epithelial Ovarian Cancer Clinical Trial

Official title:
Single -Arm, Multicenter Phase-II Trial for Catumaxomab and Chemotherapy in Patients With Recurrent Ovarian Cancer to Investigate the Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy Regimes

Status Completed

Clinical Trial Summary

Single -arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Recurrent Epithelial Ovarian Cancer

Clinical Trial Details

NCT number	NCT01815528
Study type	Interventional
Source	Charite University, Berlin, Germany
Contact
Status	Completed
Phase	Phase 2
Start date	March 2013
Completion date	February 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05444270` - Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer	N/A
Completed	`NCT01853644` - Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Phase 2
Active, not recruiting	`NCT05335993` - A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	Phase 2
Recruiting	`NCT05700669` - Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT02785250` - Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer	Phase 1/Phase 2
Terminated	`NCT01334047` - Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients	Phase 1/Phase 2